RLM Realm Thera.

TIDMPURI

RNS Number : 9509T

PuriCore Plc

19 December 2012

THIS ANNOUNCEMENT IS FOR INFORMATION ONLY AND DOES NOT CONSTITUTE OR FORM PART OF AN OFFER OF OR INVITATION TO SELL OR ISSUE OR ANY SOLICITATION OF ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SECURITIES FOR SALE IN ANY JURISDICTION NOR SHALL IT (NOR ANY PART OF IT) FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, OR ACT AS AN INDUCEMENT TO ENTER INTO, ANY CONTRACT OR COMMITMENT TO DO SO.

19 December 2012

PuriCore plc

("PuriCore" or the "Company")

PUBLICATION OF PROSPECTUS

PuriCore (LSE: PURI), the water-based, clean technology company, today announces the publication of its prospectus (the "Prospectus") in connection with the restructuring of its Convertible Loan Notes and a Placing of new Ordinary Shares to raise approximately GBP2.3 million, details of which were announced earlier today.

The Prospectus has been approved by the UK Listing Authority. A copy of the prospectus is available from http://investor.puricore.com/agm and a copy has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.hemscott.com/nsm.do.

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/9509T_-2012-12-19.pdf

Enquiries

 
 PuriCore Plc 
 Michael Ashton/Jennifer Guinan       Tel: +1 610 410 8111 
 
 Peel Hunt LLP (Sponsor, Financial 
  Adviser and Broker) 
 Daniel Harris                        Tel: +44 (0) 20 7418 8900 
 
 FTI Consulting 
 Susan Stuart/Simon Conway/Victoria   Tel: +44 (0) 20 7831 3113 
  Foster Mitchell 
 

About PuriCore

PuriCore is a water-based, clean technology company developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's antimicrobial technology and complementary products are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is a leading provider of a broad suite of products and services for compliant endoscopic decontamination in NHS and private hospitals. In the US, PuriCore's Wound Care technology is used by hospitals, wound care centres, nursing homes, and home healthcare providers to treat chronic and acute wounds. The Wound Care technology also provides partnership opportunities in new Health Sciences segments including Dermatology and Animal Health. In the Food & Agriculture market both Sterilox Fresh and FloraFresh Solution provide savings to supermarket retailers in labour costs and improvements in inventory loss of fresh produce and floral products. Sterilox Fresh is also used to sanitise fresh fruits and vegetables in US and Canadian supermarkets. In addition, the Company is progressing in its research and development programmes at Oxford University on the use of its technology as an agricultural fungicide.

PuriCore has operations in Malvern, Pennsylvania, US, and in Stafford and Clevedon, UK.

To receive additional information on PuriCore, visit www.puricore.com, which does not form part of this announcement.

Peel Hunt LLP, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for the Company in relation to the restructuring of the Convertible Loan Notes and the Placing and will not be responsible to any person other than the Company for providing the protections afforded to its clients nor for advising any other person in relation to the restructuring of the Convertible Loan Notes and the Placing or any other transaction or arrangement referred to in this announcement, apart from the responsibilities and liabilities, if any, which may be imposed on Peel Hunt by applicable laws and regulations.

The Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933, as amended, (the "Securities Act") and may not be offered or sold in the United States or to US persons unless the Ordinary Shares are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available.

The distribution of this announcement in certain jurisdictions may be restricted by law and such distribution could result in violation of the laws of such jurisdiction. Persons into whose possession this announcement comes are required by the Company to inform themselves about, and to observe, any such restrictions.

This announcement is the sole responsibility of the Company.

Defined terms in this announcement have the same meaning as set out in the announcement published by the Company earlier today.

This information is provided by RNS

The company news service from the London Stock Exchange

END

PDIZMMMZKLGGZZM

Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024